Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지
DOI QR코드

DOI QR Code

Fluconazole prophylaxis against invasive candidiasis in very low and extremely low birth weight preterm neonates: a systematic review and meta-analysis

  • Received : 2019.11.14
  • Accepted : 2020.04.29
  • Published : 2021.04.15
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Evidence shows that fluconazole prophylaxis is an effective treatment against invasive fungal infections in preterm neonates, however, the most efficient schedule of fluconazole prophylaxis for the colonization and mortality of invasive candidiasis (IC) is unknown. Purpose: This systematic review and meta-analysis aimed to assess the efficiency of different prophylactic fluconazole schedules in controlling IC colonization, infection, and mortality in very low birth weight (VLBW) and extremely low birth weight (ELBW) infants in neonatal intensive care units. Methods: We searched the PubMed, Scopus, Embase, and Cochrane databases using the keywords "candida," "invasive candidiasis," "IC," "fluconazole prophylaxis," "preterm infants," "very low birth weight infants," "VLBW," "extremely low birth weight," and "ELBW." Results: Mortality was significantly decreased in a meta-analysis of studies using different fluconazole prophylaxis regimens. The meta-analysis also indicated a significant decrease in the incidence of IC-associated mortality in ELBW infants using the same fluconazole prophylaxis schedules. Conclusion: Future studies should explore the effectiveness of other different fluconazole prophylaxis schedules on IC colonization, infection, and mortality.

Keywords

References

  1. Benjamin DK Jr, Stoll BJ, Fanaroff AA, McDonald SA, Oh W, Higgins RD, et al. Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months. Pediatrics 2006;117:84-92. https://doi.org/10.1542/peds.2004-2292
  2. IPDTOC Working Group. Prevalence at birth of cleft lip with or without cleft palate: data from the International Perinatal Database of Typical Oral Clefts (IPDTOC). Cleft Palate Craniofac J 2011;48:66-81. https://doi.org/10.1597/09-217
  3. Rao S, Ali U. Systemic fungal infections in neonates. J Postgrad Med 2005;51 Suppl 1:S27-9.
  4. Steinbach WJ. Epidemiology of invasive fungal infections in neonates and children. Clin Microbiol Infect 2010;16:1321-7. https://doi.org/10.1111/j.1469-0691.2010.03288.x
  5. Pammi M, Holland L, Butler G, Gacser A, Bliss JM. Candida parapsilosis is a significant neonatal pathogen: a systematic review and meta-analysis. Pediatr Infect Dis J 2013;32:e206-16. https://doi.org/10.1097/INF.0b013e3182863a1c
  6. Chow BD, Linden JR, Bliss JM. Candida parapsilosis and the neonate: epidemiology, virulence and host defense in a unique patient setting. Expert Rev Anti Infect Ther 2012;10:935-46. https://doi.org/10.1586/eri.12.74
  7. Arsenault AB, Bliss JM. Neonatal candidiasis: new insights into an old problem at a unique host-pathogen interface. Curr Fungal Infect Rep 2015;9:246-52. https://doi.org/10.1007/s12281-015-0238-x
  8. Kaufman D, Boyle R, Hazen KC, Patrie JT, Robinson M, Donowitz LG. Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N Engl J Med 2001;345:1660-6. https://doi.org/10.1056/NEJMoa010494
  9. Kicklighter SD, Springer SC, Cox T, Hulsey TC, Turner RB. Fluconazole for prophylaxis against candidal rectal colonization in the very low birth weight infant. Pediatrics 2001;107:293-8. https://doi.org/10.1542/peds.107.2.293
  10. Manzoni P, Stolfi I, Pugni L, Decembrino L, Magnani C, Vetrano G, et al. A multicenter, randomized trial of prophylactic fluconazole in preterm neonates. N Engl J Med 2007;356:2483-95. https://doi.org/10.1056/NEJMoa065733
  11. Parikh TB, Nanavati RN, Patankar CV, Rao S, Bisure K, Udani RH, et al. Fluconazole prophylaxis against fungal colonization and invasive fungal infection in very low birth weight infants. Indian Pediatr 2007;44:830-7.
  12. Healy CM, Campbell JR, Zaccaria E, Baker CJ. Fluconazole prophylaxis in extremely low birth weight neonates reduces invasive candidiasis mortality rates without emergence of fluconazole-resistant Candida species. Pediatrics 2008;121:703-10. https://doi.org/10.1542/peds.2007-1130
  13. Kaufman DA, Cuff AL, Wamstad JB, Boyle R, Gurka MJ, Grossman LB, et al. Fluconazole prophylaxis in extremely low birth weight infants and neurodevelopmental outcomes and quality of life at 8 to 10 years of age. J Pediatr 2011;158:759-65.e1. https://doi.org/10.1016/j.jpeds.2010.11.002
  14. Friedman S, Richardson SE, Jacobs SE, O'Brien K. Systemic Candida infection in extremely low birth weight infants: short term morbidity and long term neurodevelopmental outcome. Pediatr Infect Dis J 2000;19:499-504. https://doi.org/10.1097/00006454-200006000-00002
  15. Lee J, Kim HS, Shin SH, Choi CW, Kim EK, Choi EH, et al. Efficacy and safety of fluconazole prophylaxis in extremely low birth weight infants: multicenter pre-post cohort study. BMC Pediatr 2016;16:67. https://doi.org/10.1186/s12887-016-0605-y
  16. Che D, Zhou H, Li T, Wu B. Duration and intensity of fluconazole for prophylaxis in preterm neonates: a meta-analysis of randomized controlled trials. BMC Infect Dis 2016;16:312. https://doi.org/10.1186/s12879-016-1645-5
  17. Kaufman D, Boyle R, Hazen KC, Patrie JT, Robinson M, Grossman LB. Twice weekly fluconazole prophylaxis for prevention of invasive Candida infection in high-risk infants of <1000 grams birth weight. J Pediatr 2005;147:172-9. https://doi.org/10.1016/j.jpeds.2005.03.036
  18. Leonart LP, Tonin FS, Ferreira VL, Tavares da Silva Penteado S, de Araujo Motta F, Pontarolo R. Fluconazole doses used for prophylaxis of invasive fungal infection in neonatal intensive care units: a network meta-analysis. J Pediatr 2017;185:129-35.e6. https://doi.org/10.1016/j.jpeds.2017.02.039
  19. Dorland WAM. Dorland's illustrated medical dictionary. 32nd ed. Philadelphia (PA): Elsevier Health Sciences; 2011.
  20. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097. https://doi.org/10.1371/journal.pmed.1000097
  21. Lo CK, Mertz D, Loeb M. Newcastle-Ottawa Scale: comparing reviewers' to authors' assessments. BMC Med Res Methodol 2014;14:45. https://doi.org/10.1186/1471-2288-14-45
  22. Jannatdoust A, Imani V. The effect of prophylactic intravenous fluconazole on the clinical outcome of preterm infants during hospitalization. 2015.
  23. Aghai ZH, Mudduluru M, Nakhla TA, Amendolia B, Longo D, Kemble N, et al. Fluconazole prophylaxis in extremely low birth weight infants: association with cholestasis. J Perinatol 2006;26:550-5. https://doi.org/10.1038/sj.jp.7211570
  24. Healy CM, Baker CJ, Zaccaria E, Campbell JR. Impact of fluconazole prophylaxis on incidence and outcome of invasive candidiasis in a neonatal intensive care unit. J Pediatr 2005;147:166-71. https://doi.org/10.1016/j.jpeds.2005.04.016
  25. Weitkamp JH, Ozdas A, LaFleur B, Potts AL. Fluconazole prophylaxis for prevention of invasive fungal infections in targeted highest risk preterm infants limits drug exposure. J Perinatol 2008;28:405-11. https://doi.org/10.1038/sj.jp.7211914
  26. Rueda K, Moreno MT, Espinosa M, Saez-Llorens X. Impact of routine fluconazole prophylaxis for premature infants with birth weights of less than 1250 grams in a developing country. Pediatr Infect Dis J 2010;29:1050-2. https://doi.org/10.1097/inf.0b013e3181e9dea2
  27. Aydemir C, Oguz SS, Dizdar EA, Akar M, Sarikabadayi YU, Saygan S, et al. Randomised controlled trial of prophylactic fluconazole versus nystatin for the prevention of fungal colonisation and invasive fungal infection in very low birth weight infants. Arch Dis Child Fetal Neonatal Ed 2011;96:F164-8. https://doi.org/10.1136/adc.2009.178996
  28. Bertini G, Perugi S, Dani C, Filippi L, Pratesi S, Rubaltelli FF. Fluconazole prophylaxis prevents invasive fungal infection in high-risk, very low birth weight infants. J Pediatr 2005;147:162-5. https://doi.org/10.1016/j.jpeds.2005.02.020
  29. Manzoni P, Arisio R, Mostert M, Leonessa M, Farina D, Latino MA, et al. Prophylactic fluconazole is effective in preventing fungal colonization and fungal systemic infections in preterm neonates: a single-center, 6-year, retrospective cohort study. Pediatrics 2006;117:e22-32. https://doi.org/10.1542/peds.2004-2227
  30. Benjamin DK Jr, Hudak ML, Duara S, Randolph DA, Bidegain M, Mundakel GT, et al. Effect of fluconazole prophylaxis on candidiasis and mortality in premature infants: a randomized clinical trial. JAMA 2014;311:1742-9. https://doi.org/10.1001/jama.2014.2624
  31. Kirpal H, Gathwala G, Chaudhary U, Sharma D. Prophylactic fluconazole in very low birth weight infants admitted to neonatal intensive care unit: randomized controlled trial. J Matern Fetal Neonatal Med 2016;29:624-8. https://doi.org/10.3109/14767058.2015.1013933
  32. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-58. https://doi.org/10.1002/sim.1186
  33. Hope WW, Castagnola E, Groll AH, Roilides E, Akova M, Arendrup MC, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp. Clin Microbiol Infect 2012;18 Suppl 7:38-52. https://doi.org/10.1111/1469-0691.12040
  34. Santolaya ME, Alvarado Matute T, de Queiroz Telles F, Colombo AL, Zurita J, et al. Recommendations for the management of candidemia in neonates in Latin America. Latin America Invasive Mycosis Network. Rev Iberoam Micol 2013;30:158-70.
  35. Figueras C, Diaz de Heredia C, Garcia JJ, Navarro M, Ruiz-Contreras J, Rossich R, et al. Recomendaciones de la Sociedad Espanola de Infectologia Pediatrica sobre diagnostico y tratamiento de la candidiasis invasiva [The Spanish Society of Paediatric Infectious Diseases (SEIP) recommendations on the diagnosis and management of invasive candidiasis]. An Pediatr (Barc) 2011;74:337.e1-337.e17. https://doi.org/10.1016/j.anpedi.2010.12.012
  36. Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 2016;62:e1-50. https://doi.org/10.1093/cid/civ933
  37. Benjamin DK Jr, Stoll BJ, Gantz MG, Walsh MC, Sanchez PJ, Das A, et al. Neonatal candidiasis: epidemiology, risk factors, and clinical judgment. Pediatrics 2010;126:e865-73. https://doi.org/10.1542/peds.2009-3412
  38. Cleminson J, Austin N, McGuire W. Prophylactic systemic antifungal agents to prevent mortality and morbidity in very low birth weight infants. Cochrane Database Syst Rev 2015;2015:CD003850.
  39. Rios JFDS, Camargos PAM, Correa LP, Romanelli RMC. Fluconazole prophylaxis in preterm infants: a systematic review. Braz J Infect Dis 2017;21:333-8. https://doi.org/10.1016/j.bjid.2017.01.008
  40. Blyth CC, Barzi F, Hale K, Isaacs D. Chemoprophylaxis of neonatal fungal infections in very low birthweight infants: efficacy and safety of fluconazole and nystatin. J Paediatr Child Health 2012;48:846-51. https://doi.org/10.1111/j.1440-1754.2012.02543.x

Cited by

  1. Fluconazole prophylaxis for prevention of invasive candidiasis in extremely preterm infants vol.64, pp.4, 2021, https://doi.org/10.3345/cep.2020.00745